TL/Btz is active against primary CD138+ MM cells and diminishes the primitive progenitor cell-enriched CD138−/CD19+/CD20+/CD27+ population while sparing normal CD34+ cells. This evidence concerns the gene CD19 and Miyoshi myopathy.